Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma.
CONCLUSIONS: BV can be given post-ASCT with an acceptable toxicity profile and produces reasonable disease-free and overall survival rates. A randomized study comparing the BV regimen to single-agent lenalidomide or bortezomib is needed.
PMID: 31434076 [PubMed - as supplied by publisher]
Source: Acta Haematologica - Category: Hematology Authors: Holmberg LA, Green D, Libby E, Becker PS Tags: Acta Haematol Source Type: research
More News: Brain | Gastroenterology | Hematology | Myeloma | Neurology | Peripheral Neuropathy | Revlimid | Stem Cell Therapy | Stem Cells | Study | Switzerland Health | Toxicology | Transplants | Velcade